The current systematic review was aimed at exploring the mesenchymal stem cell (MSC) therapy in retinitis pigmentosa (RP) patients. This study included all the studies which focused and reported the Mesenchymal stem cell therapy in retinitis pigmentosa patients. A filtration procedure was used to remove duplicates, irrelevant publications. The online databases Ovid MEDLINE, Ovid Embase, and the Cochrane Library were used to perform a literature search for publications published between 2016 and 2023, without any date or language restrictions. We used a combination of relevant search terms “MSC, MSC transplantation, Stem cell therapy, Bone marrow-derived stem cell, Adipose tissue-derived stem cell, umbilical cord-derived stem cell, and RP”. We independently identified publications and systematically screened titles, abstracts, and full texts of the collected publications. Eleven trials were evaluated, comprising two preclinical and nine clinical trials assessing mesenchymal stem cells derived from adipose tissue, bone marrow, umbilical cord, and Warton jelly cells. The effectiveness and outcomes of MSC treatment for retinitis pigmentosa varied among different types of MSCs used in therapy. However, the weak evidence regarding the safety of MSCs challenges their promise as a potential treatment for retinitis pigmentosa.
Key words: MSCs, therapy, RP, outcomes.
|
